{"id":60980,"date":"2025-03-25T10:02:53","date_gmt":"2025-03-25T09:02:53","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/citi-appointed-as-depositary-bank-for-nightingale-health-oyjs-adr-program\/"},"modified":"2025-03-25T10:02:53","modified_gmt":"2025-03-25T09:02:53","slug":"citi-appointed-as-depositary-bank-for-nightingale-health-oyjs-adr-program","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/citi-appointed-as-depositary-bank-for-nightingale-health-oyjs-adr-program\/","title":{"rendered":"Citi Appointed as Depositary Bank for Nightingale Health OYJ\u2019s ADR Program"},"content":{"rendered":"
\n

LONDON–(BUSINESS WIRE)–Citi Issuer Services, acting through Citibank N.A., has been appointed by Nightingale Health OYJ (\u201cNightingale Health\u201d) to act as depositary bank for its sponsored Level 1 American Depositary Receipt (\u201cADR\u201d) program.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nNightingale Health\u2019s ADRs are traded on the OTCQX platform under the symbol \u201cNHLTY\u201d. Each ADR represents one ordinary share of the company. Nightingale Health\u2019s underlying ordinary shares are listed and traded on the Nasdaq Helsinki Stock Exchange under the symbol \u201cHEALTH FH\u201d.\n<\/p>\n

\n\u201cWe are excited to work with Citi on our ADR program which enables U.S. investors to easily trade our shares,\u201d said Teemu Suna, Nightingale Health\u2019s CEO and Founder. \u201cOur ambitions are highly global, and the U.S represents the world’s largest healthcare market. We continue to expand our business in the market and providing U.S. investors with greater access to our firm aligns perfectly with our global growth strategy.\u201d\n<\/p>\n

\nDirk Jones, Head of Issuer Services at Citi said: \u201cBy leveraging Citi\u2019s global network, we have the ability to support issuers to expand and diversify their shareholder base by accessing global capital markets. Through our Issuer Services business, Citi offers a high-quality ADR service which will facilitate the success of Nightingale Health\u2019s Level 1 ADR program.\u201d\n<\/p>\n

\nCiti Issuer Services is a leading provider of depositary receipt services. With depositary receipt programs in over 65 markets, spanning equity and fixed-income products, Issuer Services leverages Citi\u2019s global network to provide cross-border capital market access to issuers, intermediaries, and investors.\n<\/p>\n

\nFor more information on Citi\u2019s depositary receipt services, visit www.citi.com\/dr<\/a>.\n<\/p>\n

\nAbout Citi<\/b>\n<\/p>\n

\nCiti is a preeminent banking partner for institutions with cross-border needs, a global leader in wealth management and a valued personal bank in its home market of the United States. Citi does business in more than 180 countries and jurisdictions, providing corporations, governments, investors, institutions and individuals with a broad range of financial products and services.\n<\/p>\n

\nAdditional information may be found at www.citigroup.com<\/a> | X: @Citi<\/a> | LinkedIn: www.linkedin.com\/company\/citi<\/a> | YouTube: www.youtube.com\/citi<\/a> | Facebook: www.facebook.com\/citi<\/a>\n<\/p>\n

\nAbout Nightingale Health<\/b>\n<\/p>\n

\nNightingale Health has developed the world\u2019s most advanced health check. Our solution provides risk detection for multiple chronic diseases from a single blood sample. Nightingale Health Check can be scaled to entire populations and can replace many of the current routine disease risk assessments and health screening programs for chronic diseases. Detecting disease risks comprehensively and efficiently allows effective targeting and tracking of health interventions, and better prevention of chronic diseases. Nightingale Health\u2019s mission is to build sustainable healthcare and reduce health inequalities. With every sample Nightingale Health helps to create a healthier world.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nCiti Media Contact:<\/b>
Harsha Jethnani<\/i>
harsha.jethnani@citi.com<\/i><\/a>
+65 93830872<\/i>\n<\/p>\n

\nNightingale Health Investor Contact:<\/b>
Teemu Suna, CEO<\/i>
ir@nightingalehealth.com<\/i><\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

LONDON–(BUSINESS WIRE)–Citi Issuer Services, acting through Citibank N.A., has been appointed by Nightingale Health OYJ (\u201cNightingale Health\u201d) to act as depositary bank for its sponsored Level 1 American Depositary Receipt (\u201cADR\u201d) program. Nightingale Health\u2019s ADRs are traded on the OTCQX platform under the symbol \u201cNHLTY\u201d. Each ADR represents one ordinary share of the company. Nightingale … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-60980","6":"format-standard","7":"category-industry"},"yoast_head":"\nCiti Appointed as Depositary Bank for Nightingale Health OYJ\u2019s ADR Program - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/citi-appointed-as-depositary-bank-for-nightingale-health-oyjs-adr-program\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Citi Appointed as Depositary Bank for Nightingale Health OYJ\u2019s ADR Program - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LONDON–(BUSINESS WIRE)–Citi Issuer Services, acting through Citibank N.A., has been appointed by Nightingale Health OYJ (\u201cNightingale Health\u201d) to act as depositary bank for its sponsored Level 1 American Depositary Receipt (\u201cADR\u201d) program. Nightingale Health\u2019s ADRs are traded on the OTCQX platform under the symbol \u201cNHLTY\u201d. Each ADR represents one ordinary share of the company. Nightingale ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/citi-appointed-as-depositary-bank-for-nightingale-health-oyjs-adr-program\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-25T09:02:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250325190873\/en\/386817\/22\/citi_2c-blu_pos_rgb.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/citi-appointed-as-depositary-bank-for-nightingale-health-oyjs-adr-program\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/citi-appointed-as-depositary-bank-for-nightingale-health-oyjs-adr-program\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Citi Appointed as Depositary Bank for Nightingale Health OYJ\u2019s ADR Program\",\"datePublished\":\"2025-03-25T09:02:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/citi-appointed-as-depositary-bank-for-nightingale-health-oyjs-adr-program\\\/\"},\"wordCount\":478,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/citi-appointed-as-depositary-bank-for-nightingale-health-oyjs-adr-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250325190873\\\/en\\\/386817\\\/22\\\/citi_2c-blu_pos_rgb.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/citi-appointed-as-depositary-bank-for-nightingale-health-oyjs-adr-program\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/citi-appointed-as-depositary-bank-for-nightingale-health-oyjs-adr-program\\\/\",\"name\":\"Citi Appointed as Depositary Bank for Nightingale Health OYJ\u2019s ADR Program - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/citi-appointed-as-depositary-bank-for-nightingale-health-oyjs-adr-program\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/citi-appointed-as-depositary-bank-for-nightingale-health-oyjs-adr-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250325190873\\\/en\\\/386817\\\/22\\\/citi_2c-blu_pos_rgb.jpg\",\"datePublished\":\"2025-03-25T09:02:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/citi-appointed-as-depositary-bank-for-nightingale-health-oyjs-adr-program\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/citi-appointed-as-depositary-bank-for-nightingale-health-oyjs-adr-program\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/citi-appointed-as-depositary-bank-for-nightingale-health-oyjs-adr-program\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250325190873\\\/en\\\/386817\\\/22\\\/citi_2c-blu_pos_rgb.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250325190873\\\/en\\\/386817\\\/22\\\/citi_2c-blu_pos_rgb.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/citi-appointed-as-depositary-bank-for-nightingale-health-oyjs-adr-program\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Citi Appointed as Depositary Bank for Nightingale Health OYJ\u2019s ADR Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Citi Appointed as Depositary Bank for Nightingale Health OYJ\u2019s ADR Program - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/citi-appointed-as-depositary-bank-for-nightingale-health-oyjs-adr-program\/","og_locale":"en_US","og_type":"article","og_title":"Citi Appointed as Depositary Bank for Nightingale Health OYJ\u2019s ADR Program - Pharma Trend","og_description":"LONDON–(BUSINESS WIRE)–Citi Issuer Services, acting through Citibank N.A., has been appointed by Nightingale Health OYJ (\u201cNightingale Health\u201d) to act as depositary bank for its sponsored Level 1 American Depositary Receipt (\u201cADR\u201d) program. Nightingale Health\u2019s ADRs are traded on the OTCQX platform under the symbol \u201cNHLTY\u201d. Each ADR represents one ordinary share of the company. Nightingale ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/citi-appointed-as-depositary-bank-for-nightingale-health-oyjs-adr-program\/","og_site_name":"Pharma Trend","article_published_time":"2025-03-25T09:02:53+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250325190873\/en\/386817\/22\/citi_2c-blu_pos_rgb.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/citi-appointed-as-depositary-bank-for-nightingale-health-oyjs-adr-program\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/citi-appointed-as-depositary-bank-for-nightingale-health-oyjs-adr-program\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Citi Appointed as Depositary Bank for Nightingale Health OYJ\u2019s ADR Program","datePublished":"2025-03-25T09:02:53+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/citi-appointed-as-depositary-bank-for-nightingale-health-oyjs-adr-program\/"},"wordCount":478,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/citi-appointed-as-depositary-bank-for-nightingale-health-oyjs-adr-program\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250325190873\/en\/386817\/22\/citi_2c-blu_pos_rgb.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/citi-appointed-as-depositary-bank-for-nightingale-health-oyjs-adr-program\/","url":"https:\/\/pharma-trend.com\/en\/citi-appointed-as-depositary-bank-for-nightingale-health-oyjs-adr-program\/","name":"Citi Appointed as Depositary Bank for Nightingale Health OYJ\u2019s ADR Program - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/citi-appointed-as-depositary-bank-for-nightingale-health-oyjs-adr-program\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/citi-appointed-as-depositary-bank-for-nightingale-health-oyjs-adr-program\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250325190873\/en\/386817\/22\/citi_2c-blu_pos_rgb.jpg","datePublished":"2025-03-25T09:02:53+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/citi-appointed-as-depositary-bank-for-nightingale-health-oyjs-adr-program\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/citi-appointed-as-depositary-bank-for-nightingale-health-oyjs-adr-program\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/citi-appointed-as-depositary-bank-for-nightingale-health-oyjs-adr-program\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250325190873\/en\/386817\/22\/citi_2c-blu_pos_rgb.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250325190873\/en\/386817\/22\/citi_2c-blu_pos_rgb.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/citi-appointed-as-depositary-bank-for-nightingale-health-oyjs-adr-program\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Citi Appointed as Depositary Bank for Nightingale Health OYJ\u2019s ADR Program"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60980","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=60980"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60980\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=60980"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=60980"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=60980"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}